New cohort study data shows baxter's expanded hemodialysis – known as hdx therapy – is associated with approximately 25% lower mortality rate for up to four years

Deerfield, ill.--(business wire)--baxter international inc. (nyse:bax), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as hdx therapy, enabled by theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis (hf hd). the study, “survival of expanded hemodialysis and high-flux hemodialysis patients in colombia: a cohort study,” was p.
BAX Ratings Summary
BAX Quant Ranking